Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the

Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a

BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment

BroadOak invested in Microsize, a CDMO specializing in micronization and particle size control, as part of

BroadOak invested in Kemp Proteins, a leading CDMO specializing in the production of novel proteins. The

BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. 

BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the

BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a

BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and